Compare Natera Inc. Common Stock (NTRA) vs Range Nuclear Renaissance ETF (NUKZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Range Nuclear Renaissance ETF — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Range Nuclear Renaissance ETF trades at $57.5 (market cap $668.48M). The key difference: Natera Inc. Common Stock is far larger — about 85.3× Range Nuclear Renaissance ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Range Nuclear Renaissance ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Range Nuclear Renaissance ETF for 23 Days on average.
| NTRA | NUKZ | |
|---|---|---|
Market Cap | $57.03B | $668.48M |
Volume | 1,131,157 | 55,573 |
Sector | Health | Sector/Thematic |
52-Week High | $425.64 | $76.23 |
52-Week Low | $179.42 | $58.42 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
NUKZ (Range Nuclear Renaissance Index ETF) trades at $60.37, showing minimal daily movement (+0.18%). The technical picture remains bearish with moving averages signaling strong selling pressure, though oscillators suggest neutral momentum. Recent industry developments include Google's 3.6 GW nuclear deal with Constellation Energy and record global nuclear power generation, creating positive sector tailwinds despite the ETF's current technical weakness.
The nuclear energy sector faces both significant catalysts and challenges. Strong demand from AI data centers and federal support for new projects provide growth opportunities, while supply chain bottlenecks and execution risks remain concerns. With the ETF trading near support levels, investors are watching for fundamental improvements to drive price recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Range Nuclear Renaissance ETF
Range Nuclear Renaissance ETF seeks to track companies related to the nuclear energy industry. Its holdings may include businesses involved in uranium, nuclear power generation, reactors, and nuclear services.
Read more on NUKZ →
